Recent studies of the tumor genome seek to identify cancer pathways as groups of genes in
which mutations are epistatic with one another or, specifically," mutually exclusive." Here, we …

Precision cancer medicine promises to tailor clinical decisions to patients using genomic
information. Indeed, successes of drugs targeting genetic alterations in tumors, such as …

Cancer is a heterogeneous disease with different combinations of genetic alterations driving
its development in different individuals. We introduce CoMEt, an algorithm to identify …

The prevalence of neutral mutations in cancer cell population impedes the distinguishing of
cancer-causing driver mutations from passenger mutations. To systematically prioritize the …

Although rapid progress has been made in computational approaches for prioritizing cancer
driver genes, research is far from achieving the ultimate goal of discovering a complete …

We present a novel method for the identification of sets of mutually exclusive gene
alterations in a given set of genomic profiles. We scan the groups of genes with a common …

Objective: Hepatocellular carcinoma (HCC) is a highly heterogeneous disease with a dismal
prognosis. However, driver genes and prognostic markers in HCC remain to be identified. It …

The genomic evolution inherent to cancer relates directly to a renewed focus on the
voluminous next-generation sequencing data and machine learning for the inference of …

Despite the explosion in the numbers of cancer genomic studies, metastasis is still the major
cause of cancer mortality. In breast cancer, approximately one-fifth of metastatic patients …

Background It has been widely realized that pathways rather than individual genes govern
the course of carcinogenesis. Therefore, discovering driver pathways is becoming an …